Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)
https://he01.tci-thaijo.org/index.php/IJPS
<h4>Aims and Scopes: IJPS (Isan J Pharm Sci)</h4> <p><strong>The Isan Journal of Pharmaceutical Sciences is published 4 times a year (January-March, April-June, July-September, and October-December)</strong><br />- To publish research and initiative work on broad aspects of pharmaceutical sciences and health sciences. <br />The breadth of its coverage is pharmacy practice, pharmaceutical care, pharmaceutical technology and Industrial pharmacy, pharmaceutical/medicinal chemistry, pharmacology, pharmacokinetics, pharmaceutical botany, pharmacognosy and natural products, social and administrative pharmacy, pharmacoeconomics, nutraceutical, cosmetic sciences and beauty, biotechnology, pharmacogenomics, Toxicology and Analytical pharmaceutical chemistry.<br />- To provide a forum for communicating data and comments on relevant research among academics and researchers.</p> <p><strong>Article evaluation:</strong> The <span style="text-decoration: underline;"><strong>article will be sent to</strong> <strong>3 experts</strong><strong> in the field (Referee)</strong></span> to evaluate the article by <strong>double-blind</strong>. The author does not know the name of the assessor's and organization, The Reviewer does not know the name of the author. <strong><span style="text-decoration: underline;">The consideration period is approximately 3 months</span></strong>.</p> <p><strong>Publication types: </strong>Original research article, review article</p> <p><strong>Publishing period: </strong>Four yearly (March, June, September and December)</p> <p><strong>Owner/Editorial periods: </strong>Faculty of Pharmaceutical Sciences, Khon Kaen University (KKU), 123 Mittraphap Road, Khon Kaen, 40002 Thailand.</p> <p><strong>Manuscript Submission:</strong> Manuscripts should be submitted online via the Journal website at <a href="https://tci-thaijo.org/index.php/IJPS">https://tci-thaijo.org/index.php/IJPS</a> and <strong><span style="text-decoration: underline;">Fees published 2,000 Baht/Article (Thai) </span></strong>and Fees published 50 USD/Article By <strong>QR-Code</strong></p> <p><strong><img style="height: 243px; width: 243px;" src="https://pharm.kku.ac.th/psthai/items/upload/files/20200625100152_upload.png" alt="" data-pagespeed-url-hash="1519359733" /></strong></p>คณะเภสัชศาสตร์ มหาวิทยาลัยขอนแก่น, มหาวิทยาลัยมหาสารคาม, มหาวิทยาลัยอุบลราชธานีen-USIsan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)1905-0852<p>In the case that some parts are used by others The author must Confirm that obtaining <strong>permission</strong> to use some of the <strong>original authors</strong>. And must attach evidence That the <strong>permission</strong> has been included</p>The Gap between Transgender Women and Community Pharmacists regarding The Use of Feminizing Hormones: A Qualitative Study
https://he01.tci-thaijo.org/index.php/IJPS/article/view/271744
<p>This research aimed to examine the gap between transgender women and community pharmacists regarding the use of feminizing hormones. <strong>Methods:</strong> This study was qualitative research that collected data from 21 transgender women and 23 community pharmacists in all regions of Thailand. Key informants were selected using purposive sampling combined with snowball sampling. Data were collected through in-depth interviews based on a semi-structured interview between February and October 2023. Data analysis was performed by content analysis. <strong>Results:</strong> The 21 transgender women had an average age of 29.8 ± 8.1 years. All the transgender women had knowledge about the efficacy and side effects of hormonal therapy, and they perceived positive attitudes toward the use of hormonal therapy as a tool to support them in becoming more feminine. Most transgender women purchased hormonal therapy from drug stores but learned about using hormonal therapy from transgender communities and social media, which increased the risk of incorrect medication use. Most of the transgender women have never received advice from community pharmacists about medication use, and they desired more guidance on hormonal therapy usage from community pharmacists. The 23 community pharmacists had an average age of 35.2 ± 9.1 years. All of the community pharmacists knew the efficacy and side effects of hormonal therapy. However, some of them were aware that contraceptive pills were not suitable for transgender women. Most of the pharmacists have not studied information about using hormonal therapy for transgender. They perceived those transgender women required prompt service at drug stores. Over-interviewing can make them uncomfortable, which may result in the community pharmacist lacking some details and dispensing inappropriate hormonal therapy for transgender women. <strong>Conclusion:</strong> Although most transgender women self-learned about using hormonal therapy, they still required guidance from community pharmacists. At the same time, community pharmacists expressed concerns that excessive questioning might cause discomfort for transgender women. Therefore, community pharmacists need to develop their knowledge and skills in providing healthcare services to transgender women.</p>Noppatsorn ApikulrungruengPiyakorn SiritananukulwongPonglada ApasrithongsakulChaiwat LimprasertPrompiriya Pitirattanaworranat
Copyright (c) 2025 Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)
https://creativecommons.org/licenses/by-nc-nd/4.0
2025-01-152025-01-15204116Integrating Rational Drug Use into Healthcare Education: A Qualitative Study Across Five Professions in Thailand
https://he01.tci-thaijo.org/index.php/IJPS/article/view/272574
<p>The irrational use of medicines is a global public health challenge, contributing to adverse patient outcomes, antimicrobial resistance, and escalating healthcare costs. Rational Drug Use (RDU) is critical to addressing these issues by promoting safe, effective, and appropriate medication use. However, integrating RDU into healthcare education remains inconsistent across professions. This study aimed to explore the initiatives and strategies employed by healthcare professionals and academic faculty to promote the education on RDU and incorporate its principles into their respective curricula. <strong>Material and Methods:</strong> A qualitative study was conducted to gather data between May and June 2023. Seven focus group discussions were conducted with 36 participants, including 17 members from professional councils and dean consortiums, and 19 faculty administrators and lecturers across five healthcare professions: Medicine, Dentistry, Pharmacy, Nursing, and Veterinary Medicine. Discussions followed a researcher-developed topic guide and were recorded, with verbatim transcripts subjected to thematic analysis. <strong>Results:</strong> Six major themes emerged: (1) The Memorandum of Understanding (MOU) formalized RDU competencies, requiring their inclusion in curricula and national licensing exams. (2) Professional councils and dean consortiums played key roles in setting accreditation standards and ensuring that RDU competencies are part of graduate qualifications. (3) The development of profession-specific RDU teaching guides led to variation in awareness and implementation across institutions. (4) Inconsistent management of RDU education was observed, with significant differences before and after the MOU’s introduction, leading to uneven progress across institutions. (5) A lack of standardized methods for assessing RDU learning outcomes hindered consistent evaluation of student competencies. (6) RDU in licensing exams was unevenly emphasized, with stronger incorporation in nursing and veterinary medicine compared to other fields. <strong>Conclusion:</strong> Despite progress in RDU integration, significant gaps remain in standardization and assessment across healthcare professions. Strengthening collaboration between councils and institutions is essential for improving RDU education, ensuring healthcare graduates are better equipped to promote RDU and patient safety.</p>Sisira DonsamakSiritree SuttajitPuckwipa SuwannapromTeeraporn Sadira SupapanRojjares Netthong
Copyright (c) 2025 Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)
https://creativecommons.org/licenses/by-nc-nd/4.0
2025-01-152025-01-152041735Evaluation of Pharmacist-Led Medication Reconciliation at Surgical Wards in a General Hospital
https://he01.tci-thaijo.org/index.php/IJPS/article/view/273101
<p>Medication reconciliation is a standard within the medication management system aimed at reducing medication errors that may occur. <strong>Objective:</strong> To develop the coordination of medication reconciliation and to investigate the medication errors, the duration of medication reconciliation, and the satisfaction of medical staff. <strong>Methods:</strong> The research design was a prospective descriptive study. The sample was patients in the surgical ward of a hospital and were taking at least one medication for chronic diseases. The medication reconciliation process was completed in all four steps. The analysis of medication error rates, types and severity levels of medication errors, the duration of medication reconciliation, and healthcare providers' satisfaction was conducted using descriptive statistics. Factors associated with the occurrence of medication errors were analyzed using the Chi-square test. <strong>Results:</strong> The sample size in this study consisted of 243 participants. The incidence rate of medication errors was 28.1% at admission and 15.0% at discharge. Most discrepancies in medication lists at both admission and discharge were unintentional differences made by physicians (44.4%). The most common type of medication error was omission of the original medication (79.1%), with the majority being category B errors (non-harmful as the error did not reach the patient) (64.6%). Most physicians accepted the correction suggestions (75.5%). Additionally, it was found that the length of hospital stay and the medications that patients received before discharge were significantly associated with the occurrence of medication errors (p <0.05). The median time taken by pharmacists to complete all four steps of medication reconciliation for one patient was 28 minutes (IQR 21, 33) with the steps of collecting and verifying taking the most time. Medical staff satisfaction with the medication reconciliation process was mostly at the highest level (92.4%). <strong>Conclusion:</strong> Medication reconciliation is an important process that can enhance patient safety in medication use, prevent medication errors from admission to discharge, and increase the role of pharmacists in collaborating with other multidisciplinary teams in hospitals.</p>Patawee Punuch-apaiSanguan LerkiatbunditWoranuch Saengcharoen
Copyright (c) 2025 Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)
https://creativecommons.org/licenses/by-nc-nd/4.0
2025-01-152025-01-152043650Antibacterial Consumption and Costs in Inpatients of a Community Hospital
https://he01.tci-thaijo.org/index.php/IJPS/article/view/273008
<p>The World Health Organization (WHO) has reported a continuous rise in bacterial resistance, accompanied by a decline in the effectiveness of antibiotics. This trend has led to increased mortality rates and escalating treatment costs. Surveillance and stewardship of antibacterial drug use at the hospital level represent essential strategies for the effective prevention and containment of antimicrobial resistance. <strong>Objectives:</strong> To analyze the value and consumption of injectable antibacterial drugs in Defined Daily Dose (DDD) form classified by list and group of antibacterial drugs available in Chatturat Hospital during 1 October 2021 – 30 September 2023. <strong>Methods:</strong> Descriptive research by searching for data on the prescription of injectable antibacterial drugs in inpatients at Chatturat Hospital from the HOSxP database and by using the RDUR9 program (version 63.01.01) of Health Region 9 to analyze the DDD value and calculate the prescription value based on the purchase price of each year. The data were analyzed by using descriptive statistics and simple linear regression statistics. <strong>Results:</strong> The total value of injectable antibacterial drugs for the fiscal years of 2021-2023 was found to be 2,992,767 baht. Individually, the fiscal years reported values of 907,482 baht, 887,663 baht and 1,197,622 baht, respectively. The value of injectable antibacterial drugs used increased by a mean of 14.54 percent per year. When the consumption of injectable antibacterial drugs by drug group was considered for all 3 fiscal years, it was found that the top 3 injectable antibacterial drugs were third-generation cephalosporins, lincosamide and nitroimidazoles, respectively. The top 3 items with the highest usage value were meropenem, ceftazidime and ceftriaxone at 671,797 baht, 562,080 baht and 440,217 baht or 22.45%, 17.58% and 14.71% of the total value of injectable antibacterial drugs, respectively. As for the amounts of injectable antibacterial drugs used in the DDD unit in the inpatient department in the fiscal years 2021-2023, the top three injectable antibacterial drugs in the DDD unit in the inpatient department were ceftriaxone, clindamycin and ceftazidime at 43.77, 16.34 and 11.32, respectively. <strong>Conclusions:</strong> During the study period from the fiscal years 2021 - 2023, the prescription value of injectable antibacterial drugs at Chatturat Hospital increased by a mean of 14.54% per year. The volume of injectable antibacterial drugs in the DDD unit tends was in an upward trend at a mean of 24.20% per year.</p>Panee Chaijandee
Copyright (c) 2025 Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)
https://creativecommons.org/licenses/by-nc-nd/4.0
2025-01-152025-01-152045162Effectiveness and Safety of Continuous Intravenous Infusion of Vancomycin in Non-Critically Ill Patients
https://he01.tci-thaijo.org/index.php/IJPS/article/view/275069
<p>Vancomycin is an antibiotic commonly used to treat infections caused by Gram-positive bacteria. Recent guideline has suggested to administer the drug as continuous intravenous in critically ill patients. However, there are no specific recommendations for its use in non-critically ill patients. <strong>Objective:</strong> To study the use pattern of continuous intravenous vancomycin infusion and its clinical outcomes in non-critically ill patients. <strong>Methods:</strong> A retrospective descriptive analysis was conducted on patients receiving continuous intravenous vancomycin at Srinagarind Hospital between January 1, 2010, and October 31, 2023. Effectiveness was measured by early clinical response, end-of-treatment outcomes, target attainment, and 30-day all-cause mortality. Safety outcomes were assessed using the incidence of vancomycin-induced nephrotoxicity. The relationship between vancomycin dose and the plasma drug concentration was assessed using Pearson correlation. <strong>Results:</strong> A total of 15 patients were included in the study. The most common infections in patients were bacteremia (33%) and central nervous system infections (20%). Three patients (20%) achieved the target attainment, with a mean dose of 55.5 ± 3.1 mg/kg/day. The improvement was found in 9 patients (60%) in early clinical response and 11 patients (73%) by the end of treatment. No patients experienced 30-day all-cause mortality or nephrotoxicity. A moderately positive correlation between vancomycin dose and the drug concentration was observed, with statistical significance (<em>r</em><sup>2</sup> = 0.523, p-value < 0.05). <strong>Conclusion: </strong>Continuous intravenous vancomycin appears to be an effective and safe treatment option for non-critically ill patients, with no evidence of nephrotoxicity in this study.</p>Siriluk JaisueCheardchai SoontornpasPreechaya SansanPiyathida IntananglaeAtibordee MeesingChuleephorn Pitayakittiwong
Copyright (c) 2025 Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)
https://creativecommons.org/licenses/by-nc-nd/4.0
2025-01-152025-01-152046371Incidence of thrombocytopenia in solid tumor patients received chemotherapy at Sunpasitthiprasong Hospital; a retrospective study
https://he01.tci-thaijo.org/index.php/IJPS/article/view/267491
<p>Cancer is a high incidence and mortality rate disease. Chemotherapy is a cornerstone of cancer treatment. Which has been reported not only to increase survival rate but also to develop many side effects including thrombocytopenia. This study aimed to investigate the incidence of thrombocytopenia in solid tumor patients who received chemotherapy. <strong>Methods:</strong> This study was conducted solid tumor patients received chemotherapy at Sunpasitthiprasong hospital during January 1st, 2021 – June 30th, 2021. An incidence of thrombocytopenia was analyzed by descriptive statistic. Wilcoxon Signed Ranks test was performed to analyze platelet count before and after chemotherapy treatment. To compare a length of hospital stay between patients with and without thrombocytopenia, T-Test statistics was chosen. A relationship between changing of platelet count and the number of cycles of chemotherapy and changing of other hematologic parameters were analyzed by simple linear regression. SPSS statistics program (version 29) was used for statistical analysis and data management. <strong>Results:</strong> A 415 solid tumor patients with 3,429 chemotherapy cycles were enrolled. An incidence of thrombocytopenia was 9.3% of which 89.9% had grade 1 severity. A platelet count before and after received chemotherapy was significantly decreased from 320,000 cells/mm3 to 263,000 cells/mm3 (p-value <0.05). Furthermore, this study found a relationship between an increasing of chemotherapy cycles and decreasing of platelet count and reducing of white blood cells and neutrophil. <strong>Conclusion:</strong> This study found the incidence of thrombocytopenia was 9.3%. Found a relationship between decreasing platelet count and chemotherapy cycles and changing of white blood cells and neutrophil.</p>Phitjira SanguanboonyaphongManit SaeteawNonthikun PasukmoonTanaporn JantakunParunya YanapuntSaran KitsaranJitlada Juengsamarn
Copyright (c) 2025 Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)
https://creativecommons.org/licenses/by-nc-nd/4.0
2025-01-152025-01-152047280